NEO Insider Trading

Insider Ownership Percentage: 2.40%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $79,488.00

NeoGenomics Insider Trading History Chart

This chart shows the insider buying and selling history at NeoGenomics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$50k$0$50kTotal Insider BuyingTotal Insider Selling

NeoGenomics Share Price & Price History

Current Price: $7.20
Price Change: Price Decrease of -2.771 (-27.79%)
As of 04/29/2025 12:30 PM ET

This chart shows the closing price history over time for NEO up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
JunJulAugSepOctNovDecJanFebMarApr$9.97Closing price on 04/28/25:

NeoGenomics Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for NeoGenomics (NASDAQ:NEO)

98.50% of NeoGenomics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at NEO by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$1.49Mbought$209ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$200M-$100M$0$100M$200MTotal InflowsTotal Outflows
NeoGenomics logo
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Read More on NeoGenomics

Today's Range

Now: $7.20
Low: $7.42
High: $9.93

50 Day Range

MA: $9.74
Low: $8.20
High: $11.86

52 Week Range

Now: $7.20
Low: $7.12
High: $19.12

Volume

2,004,288 shs

Average Volume

976,774 shs

Market Capitalization

$926.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.41

Who are the company insiders with the largest holdings of NeoGenomics?

NeoGenomics' top insider investors include:
  1. Alicia C Olivo (General Counsel)
Learn More about top insider investors at NeoGenomics.

Who are the major institutional investors of NeoGenomics?

NeoGenomics' top institutional shareholders include:
  1. Principal Financial Group Inc. — 0.50%
  2. Rhumbline Advisers — 0.29%
  3. HighMark Wealth Management LLC — 0.10%
  4. Advisor Resource Council — 0.07%
  5. Moody National Bank Trust Division — 0.07%
  6. State of Alaska Department of Revenue — 0.06%
Learn More about top institutional investors of NeoGenomics stock.

Which major investors are selling NeoGenomics stock?

In the previous quarter, NEO stock was sold by these institutional investors:
  1. Rhumbline Advisers
  2. Illinois Municipal Retirement Fund
  3. State of Alaska Department of Revenue
  4. Amalgamated Bank

Which major investors are buying NeoGenomics stock?

During the last quarter, NEO stock was bought by institutional investors including:
  1. Advisor Resource Council
  2. HighMark Wealth Management LLC
  3. Teacher Retirement System of Texas
  4. Principal Financial Group Inc.
  5. GAMMA Investing LLC
  6. Moody National Bank Trust Division
  7. Allspring Global Investments Holdings LLC
  8. Chicago Capital LLC